MAY 13, 2020 8:18 AM PDT

FDA Fast Tracks Vaccine for COVID-19

WRITTEN BY: Annie Lennon

Biopharmaceutical company, Moderna, has announced that the US Food and Drug Administration has approved its experimental COVID-19 vaccine for a Phase II trial. 

The vaccine, known as mRNA-1273, was developed by both Moderna and the National Institutes of Health. It was the first candidate to enter a Phase I human trial in March. Although the results of this trial remain unpublished, the FDA granted them federal approval to continue their research via Phase II trial soon. Meanwhile, the company hopes to begin phase III trials, the final trialing phase, early this summer. 

One of the reasons for the vaccine’s swift approval is that it operates via a system used to make other vaccines that has shown to be both effective and without huge risk to patients’ health. Rather than using an inactive form of COVID-19, this method instead introduces patients to synthetic RNA molecules in the hope that their body will recognize them as the virus and produce antibodies that may also fight against the real thing. 

In the vaccine’s Phase II trial, the researchers aim to assess the safety, reactogenicity and immunogenicity of two vaccinations given 28 days apart. They hope to recruit 600 healthy volunteers aged 18 and over, and will then follow each of them for 12 months after the second vaccination. 

Should the vaccine pass the Phase II trial, Moderna anticipates working closely with the US government to decide where its first doses will be delivered. To this end, the company has already begun scaling up its manufacturing capacity to rapidly distribute the vaccine once available. 

Optimistic, the company’s CEO Stephane Bancel nevertheless said that even if approved, supply of the vaccine will remain constrained for some time. Due to the number of cases of the virus globally, he added that soon, there will likely be more than one vaccine in circulation to fight the virus. 

 

Sources: CNBC, LabRoots, Clinical Trials Arena

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUN 09, 2020
Drug Discovery & Development
Arthritis Drug May Reduce COVID-19 Deaths by 45%
JUN 09, 2020
Arthritis Drug May Reduce COVID-19 Deaths by 45%
Researchers from the University of Michigan have found that tocilizumab, an immunosuppressive drug used to treat arthrit ...
JUN 14, 2020
Chemistry & Physics
Why Are There So Few Black People in STEM?
JUN 14, 2020
Why Are There So Few Black People in STEM?
On June 10th, 2020, thousands of STEM scientists and organizations around the world went on strike to protest systemic r ...
JUL 05, 2020
Neuroscience
Iron Build-up in Brain Linked to Alzheimer's
JUL 05, 2020
Iron Build-up in Brain Linked to Alzheimer's
Researchers from the Medical University of Graz in Austria have found a link between the build-up of iron in the brain&# ...
JUL 07, 2020
Drug Discovery & Development
Drug Shows Promise for ALS Treatment
JUL 07, 2020
Drug Shows Promise for ALS Treatment
Researchers have announced that an experimental drug showed promising results for a rare and inherited form of amyotroph ...
JUL 29, 2020
Cancer
Regulating Apoptosis in Prostate Cancer
JUL 29, 2020
Regulating Apoptosis in Prostate Cancer
Cancer treatments tend to work in one of a few ways. They can target the immune system, prevent cancer proliferation and ...
AUG 04, 2020
Neuroscience
Transcranial Stimulation Disrupts Fearful Memories
AUG 04, 2020
Transcranial Stimulation Disrupts Fearful Memories
Disrupting negative memory formation has been a challenge for years- involving treatments ranging from psychotherapy to ...
Loading Comments...